Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 4/2022

01-04-2022 | Human Immunodeficiency Virus | Original Paper

Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most

Authors: Morgan M. Philbin, Sadie Bergen, Carrigan Parish, Deanna Kerrigan, Elizabeth N. Kinnard, Sarah Reed, Mardge H. Cohen, Oluwakemi Sosanya, Anandi N. Sheth, Adaora A. Adimora, Jennifer Cocohoba, Lakshmi Goparaju, Elizabeth T. Golub, Michael Vaughn, José I. Gutierrez Jr., Margaret A. Fischl, Maria Alcaide, Lisa R. Metsch

Published in: AIDS and Behavior | Issue 4/2022

Login to get access

Abstract

Long-acting injectable (LAI) modalities have been developed for ART and PrEP. Women face unique barriers to LAI use yet little research has examined women’s perceptions of potential LAI HIV therapy candidates. We conducted 89 in-depth interviews at six Women’s Interagency HIV Study (WIHS) sites with women living with HIV (n = 59) and HIV-negative women (n = 30) from 2017 to 2018. Interviews were recorded, transcribed, and analyzed using thematic content analysis. Participants identified specific sub-populations who could most benefit from LAI over daily pills: (1) young people; (2) women with childcare responsibilities; (3) people with adherence-related psychological distress; (4) individuals with multiple sex partners; and (5) people facing structural insecurities such as homelessness. Women are underserved by current HIV care options and their perspectives are imperative to ensure a successful scale-up of LAI PrEP and LAI ART that prioritizes equitable access and benefit for all individuals.
Footnotes
1
Ages are reported in ranges by decade in order to maintain participant confidentiality.
 
Literature
1.
Van Tam V, Pharris A, Thorson A, Alfven T, Larsson M. “It is not that I forget, it’s just that I don’t want other people to know”: barriers to and strategies for adherence to antiretroviral therapy among HIV patients in Northern Vietnam. AIDS Care. 2011;23:139–45.PubMedCrossRef
2.
Skhosana N, Struthers H, Gray G, McIntyre J. HIV disclosure and other factors that impact on adherence to antiretroviral therapy: the case of Soweto, South Africa. Afr J AIDS Res. 2006;5:17–26.PubMedCrossRef
3.
Charania MR, Marshall KJ, Lyles CM, Crepaz N, Kay LS, Koenig LJ, et al. Identification of evidence-based interventions for promoting HIV medication adherence: findings from a systematic review of U.S.-based studies, 1996–2011. AIDS Behav. 2014;18:646–60.PubMedPubMedCentralCrossRef
4.
5.
6.
Murray M, Antela A, Mills A, Huang J, Jäger H, Bernal E, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. AIDS Behav. 2020;24:3533–44.PubMedPubMedCentralCrossRef
7.
Swindells S, Andrade-Villanueva J-F, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112–23.PubMedCrossRef
8.
9.
10.
11.
Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, et al. Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077. AIDS Behav. 2020;24:2520–31.PubMedPubMedCentralCrossRef
12.
Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331–40.PubMedCrossRef
13.
Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, et al. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: patient perspectives from the ECLAIR trial. HIV Clin Trials. 2018;19:129–38.PubMedCrossRef
14.
Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P, La Mar M, et al. Expanding the menu of HIV prevention options: a qualitative study of experiences with long-acting injectable cabotegravir as prep in the context of a phase II trial in the united states. AIDS Behav. 2018;22:3540–9.PubMedPubMedCentralCrossRef
15.
16.
Biello KB, Edeza A, Salhaney P, Biancarelli DL, Mimiaga MJ, Drainoni ML, et al. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs. AIDS Care. 2019;31:1214–20.PubMedPubMedCentralCrossRef
17.
Footer KHA, Lim S, Rael CT, Greene GJ, Carballa-Diéguez A, Giguere R, et al. Exploring new and existing PrEP modalities among female sex workers and women who inject drugs in a U.S. city. AIDS Care. 2019;31:1207–13.PubMedPubMedCentralCrossRef
18.
Simoni JM, Beima-Sofie K, Mohamed ZH, Christodoulou J, Tapia K, Graham SM, et al. Long-acting injectable antiretroviral treatment acceptability and preferences: a qualitative study among us providers, adults living with HIV, and parents of youth living with HIV. AIDS Pat Care STDs. 2019;33:104–11.CrossRef
19.
Kerrigan D, Mantsios A, Gorgolas M, Montes M-L, Pulido F, Brinson C, et al. Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS ONE. 2018;13(1):e0190487.PubMedPubMedCentralCrossRef
20.
Meyers K, Wu Y, Brill A, Sandfort T, Golub SA. To switch or not to switch: Intentions to switch to injectable PrEP among gay and bisexual men with at least twelve months oral PrEP experience. PLoS ONE. 2018;13:e0200296.PubMedPubMedCentralCrossRef
21.
Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). J Int AIDS Soc. 2019;22:e25408.PubMedPubMedCentralCrossRef
22.
Philbin MM, Parish C, Kinnard EN, Reed SE, Kerrigan D, Alcaide M, et al. A multi-site study of women living with HIV’s perceived barriers to, and interest in, long-acting injectable anti-retroviral therapy. J Acquir Immune Defic Syndr. 2020;84:263–70.PubMedPubMedCentralCrossRef
23.
Weld ED, Rana MS, Dallas RH, Camacho-Gonzalez AF, Ryscavage P, Gaur AH, et al. Interest of youth living with HIV in long-acting rntiretrovirals. J Acquir Immune Defic Syndr. 2019;80:190–7.PubMedPubMedCentralCrossRef
24.
Biello KB, Hosek S, Drucker MT, Belzer M, Mimiaga MJ, Marrow E, et al. Preferences for injectable prep among young U.S. cisgender men and transgender women and men who have sex with men. Arch Sex Behav. 2018;47:2101–7.PubMedCrossRef
25.
Philbin MM, Parish C, Kinnard E, Reed R, Kerrigan D, Alcaide M, et al. Attitudes towards long-acting injectable pre-exposure prophylaxis (PrEP) among women participating in the Women’s Interagency HIV Study (WIHS): a qualitative study across six United States cities. AIDS Behav. 2020;25:667–78.CrossRef
26.
Castor D, Meyers K, Allen S. The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment. Curr Opin HIV AIDS. 2020;15:73–80.PubMedCrossRef
27.
28.
Dubé K, Campbell DM, Perry KE, Kanazawa JT, Saberi P, Sauceda JA, et al. Reasons people living with HIV might prefer oral daily antiretroviral therapy, long-acting formulations, or future HIV remission options. AIDS Res Hum Retroviruses. 2020.
29.
Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, et al. efficacy and freedom: patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat HIV in the context of phase 3 trials. AIDS Behav. 2020;24:3473–81.PubMedCrossRef
30.
Fernandez C, van Halsema CL. Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV AIDS (Auckl). 2019;11:179–92.
31.
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595–608.PubMedPubMedCentralCrossRef
32.
33.
Currier JS. Monthly injectable antiretroviral therapy—version 1.0 of a new treatment approach. N Engl J Med. 2020;382:1164–5.PubMedCrossRef
34.
Benning L, Mantsios A, Kerrigan D, Coleman JS, Golub E, Blackstock O, et al. Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy. BMC Women’s Health. 2020;20:152.PubMedPubMedCentralCrossRef
35.
Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, et al. “I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain. Cult Health Sex. 2020;1:1–13.
36.
Buetow S. Thematic analysis and its reconceptualization as ‘saliency analysis.’ Health Serv Res Policy. 2010;15:123–5.CrossRef
37.
Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. 1967.
38.
MacQueen K, McLellan E, Kay K. Codebook development for team-based qualitative analysis. Cult Anthropol Methods. 1998;10:31–6.
39.
A Qualitative Exploration of Women’s Interest in Long-Acting Injectable antiretroviral therapy across six cities in the Women’s Interagency HIV Study: intersections with current and past injectable medication and substance use. AIDS Patient Care STDs. 2021;35:23–30.
40.
Holstad MM, Spangler S, Higgins M, Dalmida SG, Sharma S. Psychosocial characteristics associated with both antiretroviral therapy adherence and risk behaviors in women living with HIV. AIDS Behav. 2016;20:1084–96.PubMedPubMedCentralCrossRef
41.
Merenstein D, Schneider MF, Cox C, Schwartz R, Weber K, Robison E, et al. Association of child care burden and household composition with adherence to highly active antiretroviral therapy in the Women’s Interagency HIV Study. AIDS Pat Care STDs. 2009;23:289–96.CrossRef
42.
Cornelius T, Jones M, Merly C, Welles B, Kalichman MO, Kalichman SC. Impact of food, housing, and transportation insecurity on ART adherence: a hierarchical resources approach. AIDS Care. 2017;29:449–57.PubMedCrossRef
43.
MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17:86–93.PubMedPubMedCentralCrossRef
44.
Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med. 2015;20:255–65.PubMedCrossRef
45.
Sidebottom D, Ekström AM, Strömdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV—how can we improve uptake and adherence? BMC Infect Dis. 2018;18:581.PubMedPubMedCentralCrossRef
46.
Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. AIDS. 2019;33:1411–20.PubMedCrossRef
47.
Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.PubMedPubMedCentralCrossRef
48.
Thurston IB, Bogart LM, Wachman M, Closson EF, Skeer MR, Mimiaga MJ. Adaptation of an HIV medication adherence intervention for adolescents and young adults. Cogn Behav Pract. 2014;21:191–205.PubMedCrossRef
49.
Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28:841–9.PubMedPubMedCentralCrossRef
50.
51.
Courtenay WH. Constructions of masculinity and their influence on men’s well-being: a theory of gender and health. Soc Sci Med. 2000;50:1385–401.PubMedCrossRef
52.
Aleshire ME, Ashford K, Fallin-Bennett A, Hatcher J. Primary care providers’ attitudes related to LGBTQ people: a narrative literature review. Health Promot Prac. 2019;20:173–87.CrossRef
53.
Martos AJ, Wilson PA, Gordon AR, Lightfoot M, Meyer IH. “Like finding a unicorn”: Healthcare preferences among lesbian, gay, and bisexual people in the United States. Soc Sci Med. 2018;208:126–33.PubMedPubMedCentralCrossRef
54.
Philbin MM, Parker CM, Parker RG, Wilson PA, Garcia J, Hirsch JS. Gendered social institutions and preventive healthcare seeking for black men who have sex with men: the promise of biomedical HIV prevention. Arch Sex Behav. 2018;47:2091–100.PubMedPubMedCentralCrossRef
55.
Jaiswal J, Francis MD, Singer SN, Dunlap KB, Cox AB, Greene R. “Worn out”: coping strategies for managing antiretroviral treatment fatigue among urban people of color living with HIV who were recently disengaged from outpatient HIV care. J HIV/AIDS Soc Serv. 2020;19:173–87.CrossRef
56.
Merenstein DJ, Schneider MF, Cox C, Schwartz R, Weber K, Robison E, et al. Association between living with children and adherence to highly active antiretroviral therapy in the Women’s Interagency HIV Study. Pediatrics. 2008;121:e787–93.PubMedCrossRef
57.
Myers JE, Ellman TM, Westhoff C. Injectable agents for pre-exposure prophylaxis: lessons learned from contraception to inform HIV prevention. Cur Opin HIV AIDS. 2015;10:271–7.CrossRef
58.
Stein MD, Crystal S, Cunningham WE, Ananthanarayanan A, Andersen RM, Turner BJ, et al. Delays in seeking HIV care due to competing caregiver responsibilities. Am J Public Health. 2000;90:1138–40.PubMedPubMedCentralCrossRef
59.
Peitzmeier S, Tomko C, Wingo E, Sawyer A, Sherman S, Glass N, et al. Acceptability of pre-exposure prophylaxis and vaginal rings for HIV prevention among female sex workers in Baltimore. MD AIDS Care. 2017;29:1453–7.CrossRef
60.
61.
Glick JL, Russo R, Jivapong B, Rosman L, Pelaez D, Footer KHA, et al. The PrEP care continuum among cisgender women who sell sex and/or use drugs globally: a systematic review. AIDS Behav. 2020;24:1312–33.PubMedPubMedCentralCrossRef
62.
Mendenhall E, Singer M. What constitutes a syndemic? Methods, contexts, and framing from 2019. Curr Opin HIV AIDS. 2020;15:213–7.PubMed
63.
Jain JP, Strathdee SA, Patterson TL, Semple SJ, Harvey-Vera A, Magis-Rodríguez C, et al. Perceived barriers to pre-exposure prophylaxis use and the role of syndemic factors among female sex workers in the Mexico-United States border region: a latent class analysis. AIDS Care. 2020;32:557–66.PubMedCrossRef
64.
Friedland GH. HIV medication adherence: the intersection of biomedical, behavioral, and social science research and clinical practice. J Acquir Immune Defic Syndr. 2006;43:S3.PubMedCrossRef
65.
Paul C, Skegg DC, Williams S. Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation. Contraception. 1997;56:209–14.PubMedCrossRef
66.
Davidson AR, Kalmuss D, Cushman LF, Romero D, Heartwell S, Rulin M. Injectable contraceptive discontinuation and subsequent unintended pregnancy among low-income women. Am J Public Health. 1997;87:1532–4.PubMedPubMedCentralCrossRef
67.
Havens JP, Scarsi KK, Sayles H, Klepser DG, Swindells S, Bares SH. Acceptability and feasibility of a pharmacist-led human immunodeficiency virus pre-exposure prophylaxis program in the midwestern United States. Open Forum Infect Dis. 2019;6:ofz365.PubMedPubMedCentralCrossRef
68.
69.
Willie TC, Stockman JK, Keene DE, Calabrese SK, Alexander KA, Kershaw TS. Social networks and its impact on women’s awareness, interest, and uptake of HIV pre-exposure prophylaxis (PrEP): implications for women experiencing intimate partner violence. J Acquir Immune Defic Syndr. 2019;80:386–93.PubMedPubMedCentralCrossRef
70.
Beymer MR, Holloway IW, Pulsipher C, Landovitz RJ. Current and future PrEP medications and modalities: on-demand, injectables, and topicals. Curr HIV/AIDS Rep. 2019;16:349–58.PubMedPubMedCentralCrossRef
Metadata
Title
Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most
Authors
Morgan M. Philbin
Sadie Bergen
Carrigan Parish
Deanna Kerrigan
Elizabeth N. Kinnard
Sarah Reed
Mardge H. Cohen
Oluwakemi Sosanya
Anandi N. Sheth
Adaora A. Adimora
Jennifer Cocohoba
Lakshmi Goparaju
Elizabeth T. Golub
Michael Vaughn
José I. Gutierrez Jr.
Margaret A. Fischl
Maria Alcaide
Lisa R. Metsch
Publication date
01-04-2022
Publisher
Springer US
Published in
AIDS and Behavior / Issue 4/2022
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03483-7

Other articles of this Issue 4/2022

AIDS and Behavior 4/2022 Go to the issue

Original Paper

Blood Pressure, Depression, and Suicidal Ideation Among Pregnant Women with HIV

Original Paper

PrEP Use and Correlates of Use Among a Large, Urban Sample of Men and Transgender Persons Who Have Sex with Men

Original Paper

HIV Service Interruptions During the COVID-19 Pandemic in China: The Role of COVID-19 Challenges and Institutional Response from Healthcare Professional’s Perspective

Original Paper

Patient-Reported Treatment Satisfaction and Quality of Life Among People Living with HIV Following the Introduction of Dolutegravir-Based ART Regimens in Ukraine

Original Paper

Evaluation of SARS-CoV-2 Antibodies and the Impact of COVID-19 on the HIV Care Continuum, Economic Security, Risky Health Behaviors, and Mental Health Among HIV-Infected Individuals in Vietnam

Original Paper

Experiences of Transgender Women Who Used a Dual HIV/Syphilis Rapid Self-test to Screen Themselves and Potential Sexual Partners (the SMARTtest Study)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits